AI in Pharmaceuticals: Unlocking Potential for the Future of Medicine
Artificial intelligence in pharmaceutical research and development (R&D) is making waves, and Sanofi CEO Paul Hudson gives us some insight into the major impact AI is having on drug discovery and development.
Sanofi is seeing great results with AI models, showing over 80% prediction accuracy and significant improvement through active learning. The use of AI and machine learning has enabled the company to increase the number of clinical trials and to quadruple their pipeline value between 2019 and 2023. With AI, we are creating new therapies and unlocking previously undruggable targets for patients who are currently without treatment options.
However, there are challenges ahead for the pharma industry to fully unlock the potential of AI. The regulation of AI, pricing restrictions, access to capital for biotech startups, and building trust with new models for clinical trial design are all major concerns that will greatly impact the path forward.
The future of medicine is on the cusp of a great era of discovery, and the adoption of AI as a tool for medical research could fundamentally change the field of medicine. The question is, are we ready to face the challenges that come with leveraging artificial intelligence in the pharmaceutical sector? Share your thoughts on the potential of AI in medicine. What do you think pharmaceutical industry should do address these challenges? Let us know in the comments.
IntelliPrompt curated this article: Read the full story at the original source by clicking here